Prothena Corporation plc Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for PRTA, updated each market day.
PRTA AI Sentiment
AI predicts Prothena Corporation plc Ordinary Shares stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Prothena Corporation plc Ordinary Shares
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Sector
Exchange
Market Cap
$569,552,949
Cap Tier
Employees
67
Headquarters
DUBLIN 2, L2
Listed Since
Dec. 18, 2012
Website
PRTA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PRTA Volatility
Prothena Corporation plc Ordinary Shares has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
